The newly unveiled 2018 Canadian federal budget announced on Tuesday (February 27) offers cannabis investors a closer look into how the legal product will be taxed in the future.

Delivered by Finance Minister Bill Morneau, the document called “Equality + Growth, A Strong Middle Class,” presented all the spending done by the federal government to regulate the cannabis industry.


The budget indicates an excise duty framework is being proposed for the majority of cannabis products set to be available to consumers after the legalization of cannabis becomes official later this year.

Cannabis products with low amounts of tetrahydrocannabinol (THC) will not be taxed. Neither will pharmaceutical items derived from cannabis, as long as they have a Drug Identification Number and are only available to patients with a prescription.

Taxing for cannabis products will come down to two options: whichever is the highest applicable per product, either a $1 per gram standard or 10 percent of a product price.

The budget said:

“Under the framework, excise duties will be imposed on federally licensed producers at the higher of a flat rate applied on the quantity of cannabis contained in a final product, or a percentage of the sale price of the product sold by a federal licensee.

The proposed tax will kick off once sales of recreational cannabis become available in retail.

 

Cannabis - Will The Fortune 500 Join The Party?

 
Our Exclusive FREE Report Contains Information You NEED To Know About Cannabis Stock Investing!
 

Patient advocacy group ‘outraged’ over budget proposals

A cannabis patients advocacy group, however, expressed disappointment on the Canadian budget. Canadians for Fair Access to Medical Marijuana (CFAMM) issued a statement saying they were “outraged” to find out the limits of the products that won’t be taxed.

CFAMM acknowledge the tax won’t affect products with low to no amounts of THC but said those products are actually a minority among the patient population and represent a small representation of use.

The government will exempt some products such as non-THC and low-THC medicine from the excise tax but those products represent a small minority of those used by patients. “It’s quite clear that Canadians understand that taxing medical cannabis is unfair and wrong,” Jonathan Zaid executive director of CFAMM stated.

“Exempting a small minority of patients does not address the affordability issue and implies some patients are more legitimate than others,” Zaid commented.

The actual breakdown of the tax will be split with 75 percent going to the Canadian provinces and territorial governments. The federal government will keep the remainder 25 percent. However, that sum will be capped annually at $100 million for the first two years after legalization.

All the extra money, in this case, will be sent back to the provinces as part of a special arrangement between the two levels of government. The arranged sums are expected to be delivered to municipalities and local communities due to, according to the budget, their role on “the front lines of legalization.”

 

Cannabis - Will The Fortune 500 Join The Party?

 
Our Exclusive FREE Report Contains Information You NEED To Know About Cannabis Stock Investing!
 

Dan Kelly Dan Kelly president, CEO and chair Canadian Federation of Independent Business told Global News he is worried the government is asking for too much with this proposed tax.

“I think a smarter strategy would be to start with a very reasonable level of taxation to ensure that we get the business above ground before we start ratcheting it up,” he said.

A report on the entire budget prepared by business law firm Aird and Berlis indicated cannabis cultivators and manufacturers will now be required to get a license from Canada Revenue Agency (CRA) and “remit the excise duty, where applicable.”

Federal government will invest in cannabis research

The budget also included information on other areas related to the emerging cannabis industry the government plans to invest in. The Mental Health Commission will receive $10 million over five years to “assess the impact of cannabis use on the mental health of Canadians.”

Another $10 million, also over five years, will be given to the Canadian Centre on Substance Use and Addiction for research purposes.

It was also revealed how much will the government invest in the public education surrounding cannabis per year. Public education will get $18 million in 2018-2019, which then will go up to $16 million from the 2019-2020 cycle until the year 2023, resulting in a total $83 million campaign.

Investor Takeaway

Advocates of the industry have long argued for a complete removal of a tax on medical cannabis products. With the initial comments from CFAMM, it will be interesting to see how companies in the space react to their actions attempting to convince the government to remove the tax on medical products.

Observers of the cannabis space will also have to keep a close eye on the impact the tax on recreational products will have in deterring the illegal marijuana market.

Don’t forget to follow us @INN_Cannabis for real-time news updates!

Securities Disclosure: I, Bryan Mc Govern, hold no direct investment interest in any company mentioned in this article.

 

Cannabis - Will The Fortune 500 Join The Party?

 
Our Exclusive FREE Report Contains Information You NEED To Know About Cannabis Stock Investing!
 

Ayurcann (CSE:AYUR) entered into a joint venture with Bazelet Group, Israel’s largest privately held medical cannabis company. Ayurcann CEO Igal Sudman shared the company’s excitement about bringing unique terpene-enriched medicinal cannabis to the Canadian marketplace. 

“Canada is a very closed-loop country, and the opportunity to bring a variety of different enhancement and technologically advanced products is very important to us. The relationship that we formed with Bazelet is going to enhance our offerings into the Canadian marketplace,” Sudman said. 

Bazelet has launched multiple lines of terpene-enriched cannabis oils; each one is specifically designed for various indications, symptoms and personal needs. The company’s terpene-enriched products are optimized for women’s health, for elderly population needs, for specific types of pains (muscle, joint, neuropathic) and for improved night sleep. 

According to Sudman, there are a lot of larger companies that have tried to do this, but none have been able to successfully bring innovation into the market. Ayurcann is rapidly forging partnerships with several companies worldwide, including Cannmart, Patient Choice and Kindred Partners.

“We’re growing the business, customer base, relationships and partnerships worldwide. We’re bringing the latest technology into Canada, and enhancing not only our company, but the investors’ value moving forward,” added Sudman. 

Watch the full interview with Ayurcann CEO Igal Sudman above.

Keep reading... Show less

Trulieve Cannabis Corp. (CSE: TRUL) (OTCQX: TCNNF) (“Trulieve” or “the Company”), a leading and top-performing cannabis company based in the United States announced today the opening of a new Florida dispensary, the Company’s 91st nationwide.

The latest dispensary, located in Winter Park , supports Trulieve’s goal of ensuring medical cannabis patients across Florida have safe, reliable access to the medications they rely on. The dispensary expands access throughout Central Florida , joining four locations throughout nearby Orlando .

Keep reading... Show less

Nextleaf Solutions Ltd. (CSE: OILS) (OTCQB: OILFF) (“Nextleaf”, “OILS”, or the “Company”), the world’s most innovative cannabis extractor, is pleased to announce that the United States Patent and Trademark Office has granted the Company a patent pertaining to the extraction and purification of THC and CBD.

The Company believes it has developed defendable intellectual property around the most efficient methods for producing THC and CBD distillate at scale within a regulated market. Nextleaf owns 15 U.S. patents and has been issued over 80 patents globally.

Keep reading... Show less

Cannabis Company Executives share vision, answer questions live at VirtualInvestorConferences.com

Virtual Investor Conferences in partnership with KCSA Strategic Communications and ATB Capital Markets today announced the agenda for the upcoming Cannabis Industry Virtual lnvestor Conference. Individual investors, institutional investors, advisors and analysts are invited to attend. The two-day program begins at 9:30 AM ET on Tuesday June 29 th .

Keep reading... Show less

Acquisition solidifies Canopy Growth’s leadership position in the Canadian recreational market

Canopy Growth Corporation (“Canopy”) (TSX: WEED) (NASDAQ: CGC) and The Supreme Cannabis Company, Inc. (“Supreme”) (TSX: FIRE) (OTCQX: SPRWF) (FRA: 53S1) are pleased to announce the completion of the previously announced arrangement (the “Arrangement”) whereby Canopy has acquired all of the issued and outstanding common shares of Supreme (the “Supreme Shares”).

Keep reading... Show less